Cancer Institute A national cancer institute
designated cancer center

Christopher H. Contag

Publication Details

  • IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy CANCER IMMUNOLOGY IMMUNOTHERAPY Helms, M. W., Prescher, J. A., Cao, Y., Schaffert, S., Contag, C. H. 2010; 59 (9): 1325-1334


    Cytokine-induced killer (CIK) cells are T cell derived ex vivo expanded cells with both NK and T cell properties. They exhibit potent anti-tumor efficacy against various malignancies in preclinical models and have proven safe and effective in clinical studies. We combined CIK cell adoptive immunotherapy with IL-12 cytokine immunotherapy in an immunocompetent preclinical breast cancer model. Combining CIK cells with IL-12 increased anti-tumor efficacy in vivo compared to either therapy alone. Combination led to full tumor remission and long-term protection in 75% of animals. IL-12 treatment sharply increased the anti-tumor efficacy of short-term cultured CIK cells that exhibited no therapeutic effect alone. Bioluminescence imaging based in vitro cytotoxicity and in vivo homing assays revealed that short-term cultured CIK cells exhibit full cytotoxicity in vitro, but display different tumor homing properties than fully expanded CIK cells in vivo. Our data suggest that short-term cultured CIK cells can be "educated" in vivo, producing fully expanded CIK cells upon IL-12 administration with anti-tumor efficacy in a mouse model. Our findings demonstrate the potential to improve current CIK cell-based immunotherapy by increasing efficacy and shortening ex vivo expansion time. This holds promise for a highly efficacious cancer therapy utilizing synergistic effects of cytokine and cellular immunotherapy.

    View details for DOI 10.1007/s00262-010-0860-y

    View details for Web of Science ID 000279198000003

    View details for PubMedID 20532883

Stanford Medicine Resources:

Footer Links: